Linking higher amyloid beta 1‐38 (Aβ(1‐38)) levels to reduced Alzheimer's disease progression risk

This study not only replicates but also extends the existing findings on the role of Aβ(1-38) (amyloid beta 1-38) in Alzheimer's disease (AD) in humans in vivo. Higher baseline Aβ(1-38) levels were associated with a decreased risk of conversion to AD dementia in subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Different linear-mixed regression models suggest an association between higher Aβ(1-38) baseline levels and slower Preclinical Alzheimer's Cognitive Composite (PACC) and Clinical Dementia Rating Sum of Boxes (CDR-SB) decline. Including Aβ(1-40) beyond Aβ(1-38) in the model confirmed a link between Aβ(1-38) and PACC decline, but showed no association of Aβ(1-38) on CDR-SB and Mini-Mental State Examination (MMSE) decline. The impact of short Aβ isoforms in AD progression might have been under-investigated These findings underscore the urgent need for additional research on the role of these shorter Aβ peptides in AD, as they may hold key insights for future therapeutic strategies.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-01-27
DOI
https://doi.org/10.1002/alz.14545
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Linking higher amyloid beta 1‐38 (Aβ(1‐38)) levels to reduced Alzheimer's disease progression risk

Emrah Düzel, Silka Dawn Freiesleben, Jens Wiltfang, Ayda Rostamzadeh et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

Linking higher amyloid beta 1‐38 (Aβ(1‐38)) levels to reduced Alzheimer's disease progression risk

Emrah Düzel, Silka Dawn Freiesleben, Jens Wiltfang, Ayda Rostamzadeh, Robert Perneczky, Annika Spottke, Oliver Peters, Claudia Bartels, Stefan Teipel, Frederic Brosseron, Matthias Schmid, Boris‐Stephan Rauchmann, Sandra Roeske, Luca Kleineidam, Katharina Büerger, Klaus Fließbach, Josef Priller, Daniel Janowitz, Ingo Kilimann, Julian Hellmann‐Regen, Anja Schneider, Michael T. Heneka, Luisa‐Sophie Schneider, Wenzel Glanz, Matthias H. Munk, Melina Stark, Gerard van Breukelen, Nina Roy‐Kluth, Xiao Wang, Eike Jakob Spruth, Christoph Laske, Michael Wagner, Frank Jessen
article en

Abstract

This study not only replicates but also extends the existing findings on the role of Aβ(1-38) (amyloid beta 1-38) in Alzheimer's disease (AD) in humans in vivo. Higher baseline Aβ(1-38) levels were associated with a decreased risk of conversion to AD dementia in subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Different linear-mixed regression models suggest an association between higher Aβ(1-38) baseline levels and slower Preclinical Alzheimer's Cognitive Composite (PACC) and Clinical Dementia Rating Sum of Boxes (CDR-SB) decline. Including Aβ(1-40) beyond Aβ(1-38) in the model confirmed a link between Aβ(1-38) and PACC decline, but showed no association of Aβ(1-38) on CDR-SB and Mini-Mental State Examination (MMSE) decline. The impact of short Aβ isoforms in AD progression might have been under-investigated These findings underscore the urgent need for additional research on the role of these shorter Aβ peptides in AD, as they may hold key insights for future therapeutic strategies.

Alzheimer s & DementiaVol. 21(2)
University of Bonn (DE), University of Cologne (DE), University of Luxembourg (LU), University Hospital Bonn (DE), German Center for Neurodegenerative Diseases (DE), LMU Klinikum (DE), Maastricht University (NL), Humboldt-Universität zu Berlin (DE), Zimmer Biomet (Germany) (DE), Munich Cluster for Systems Neurology (DE), UK Dementia Research Institute (GB), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE), Hertie Institute for Clinical Brain Research (DE), University of Rostock (DE), Imperial College London (GB), University of Aveiro (PT), Technical University of Munich (DE), University of Göttingen (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), University of Tübingen (DE), Ludwig-Maximilians-Universität München (DE), University of Sheffield (GB), Otto-von-Guericke-Universität Magdeburg (DE), University of Edinburgh (GB)
Universiteit Maastricht, Deutsches Zentrum für Neurodegenerative Erkrankungen
Openalex Percentile: Top 98%
Alzheimer's disease research and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.